KKR is selling its 10% stake in Nordic Bioscience, a Denmark-based global leader in biomarker development, to the company’s founder and majority shareholder, Claus Christiansen.
KKR invested in Nordic Bioscience in 2021 through its Health Care Strategic Growth strategy,
supporting the company as it continued to expand its biomarker capabilities and strengthen
its position across R&D services, clinical diagnostics and drug development.
Over the past five years, the company has doubled revenue and strengthened its position in biomarker development, expanding its capabilities across R&D services, and clinical diagnostics, according to Kugan Sathiyanandarajah, partner and head of KKR’s European Healthcare Private Equity and Healthcare Strategic Growth.
In connection with the transaction, chair Håkan Björklund has decided to step down from the board, and Christiansen will assume the role.
